Thalidomide induced acute worsening of Parkinson's disease

Movement Disorders

Volumn 24, Issue 12, 2009, Pages 1863-1864

  Crystal, Sara C ^a   Leonidas, John ^b   Jakubowski, Ann ^c   Di Rocco, Alessandro ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBIDOPA PLUS LEVODOPA; ENTACAPONE; PREDNISONE; ROPINIROLE; THALIDOMIDE;

AGED; CASE REPORT; DIAGNOSTIC ERROR; DISEASE CONTROL; DISEASE COURSE; DRUG DOSE INCREASE; DRUG WITHDRAWAL; FATIGUE; HUMAN; LETTER; MALAISE; MALE; MEDICAL ASSESSMENT; MOTOR DYSFUNCTION; MYELOFIBROSIS; MYELOID METAPLASIA; PARKINSON DISEASE; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT RESPONSE; UNIFIED PARKINSON DISEASE RATING SCALE;

AGED; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; PARKINSON DISEASE; PRIMARY MYELOFIBROSIS; THALIDOMIDE;

EID: 70450085625     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22497     Document Type: Letter

References (5)

1. Onofrj M, Thomas O. Acute akinesia in Parkinson's disease. Neurology 2005;54:1162-1169.
2. Boireau A, Bordier F, Dubedat P, Peny C, Imperato A. Thalidomide reduces MPTP-induced decrease in striatal dopamine levels in mice. Neurosci Lett 1997;234:123-126. (Pubitemid 27452108)
3. Greig NH, Mattson MP, Perry T, et al. New therapeutic strategies and drug candidates for neurodegenerative diseases: p53 and TNF-alpha inhibitors, and GLP-1 receptor agonists. Ann NY Acad Sci 2004;1035:290-315. (Pubitemid 40362340)
4. Ryu JK, McLarnon JG. Thalidomide inhibition of perturbed vasculature and glial-derived tumor necrosis factor-alpha in an animal model of inflamed Alzheimer's disease brain. Neurobiol Dis 2008;29:254-266.
5. Kiaei M, Petri S, Kipiani K, et al. Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurosci 2006;26:2467-2473. (Pubitemid 44699007)